Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0EOMCN
ADC Name
BL-M02D1
Synonyms
BL M02D1; BLM02D1
   Click to Show/Hide
Organization
Sichuan Baili Pharmaceutical Co., Ltd.; Systimmune, Inc.; Chengdu Bailidote Biological Pharmaceutical Co., Ltd.
Drug Status
Phase 1
Indication
In total 2 Indication(s)
Non-small cell lung cancer [ICD11:2C25]
Phase 1
Triple negative breast cancer [ICD11:2C60-2C65]
Phase 1
Drug-to-Antibody Ratio
8
Antibody Name
Undisclosed
Antigen Name
Tumor-associated calcium signal transducer 2 (TACSTD2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05385692
Phase 1
Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of injectable BL-M02D1 in patients with locally advanced or metastatic gastrointestinal tumors or other solid tumors.

   Click to Show/Hide
Undisclosed  NCT05339685
Phase 1
Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of injectable BL-M02D1 in patients with locally advanced or metastatic triple negative breast cancer or other solid tumors.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05385692  Clinical Status Phase 1
Clinical Description Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of injectable BL-M02D1 in patients with locally advanced or metastatic gastrointestinal tumors or other solid tumors.
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT05339685  Clinical Status Phase 1
Clinical Description Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of injectable BL-M02D1 in patients with locally advanced or metastatic triple negative breast cancer or other solid tumors.
References
Ref 1 Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of Injectable BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors, NCT05385692
Ref 2 Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of Injectable BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors, NCT05339685

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.